Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

By Dr. Matthew Watson

MEDIA RELEASE

See more here:
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Related Post

• Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP - December 9th, 2024
• Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s... - December 9th, 2024
• Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting - December 9th, 2024
• Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory... - December 9th, 2024
• Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on... - December 9th, 2024
• Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal... - December 9th, 2024
• Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or... - December 9th, 2024
• Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With... - December 9th, 2024
• DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with... - December 9th, 2024
• Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin... - December 9th, 2024
• Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic... - December 9th, 2024
• C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become... - December 9th, 2024
• Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML - December 9th, 2024
• Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma - December 9th, 2024
• Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th... - December 9th, 2024
• Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat - December 9th, 2024
• Zelixir's New Factory to Revolutionize Natural Fragrance Production with ‘AI+Synthetic Biology’ - December 9th, 2024
• Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function - December 9th, 2024
• AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related... - December 9th, 2024
• Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders - December 9th, 2024
• Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives - November 29th, 2024
• CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - November 29th, 2024
• Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 29th, 2024
• Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel - November 29th, 2024
• Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 29th, 2024
• PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area - November 29th, 2024
• SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers - November 29th, 2024
• Coherus Management to Participate in the 2024 Citi Global Healthcare Conference - November 29th, 2024
• Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates - November 29th, 2024
• Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024 - November 29th, 2024
• Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference - November 29th, 2024
• QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis - November 29th, 2024
• Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq - November 29th, 2024
• Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia - November 29th, 2024
• Celularity Inc. Announces Receipt of Nasdaq Notification - November 29th, 2024
• HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms - November 29th, 2024
• Kane Biotech Announces Third Quarter 2024 Financial Results - November 29th, 2024
• Rakovina Therapeutics Announces Private Placement Offering - November 29th, 2024
• MEDSIR, Featured Company at the Shanghai International Medical Oncology Symposium (7th SIMOS) - November 29th, 2024
• Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million - November 29th, 2024
• Panbela Provides Business Update and Reports Q3 2024 Financial Results - November 15th, 2024
• Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability - November 15th, 2024
• Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - November 15th, 2024
• TFF Pharmaceuticals Announces It Will Wind Down Operations - November 15th, 2024
• Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - November 15th, 2024
• GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for... - November 15th, 2024
• Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update - November 15th, 2024
• HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights - November 15th, 2024
• Lowell Farms Inc. Announces Unaudited Third Quarter 2024 Financial and Operational Results - November 15th, 2024
• Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons... - November 15th, 2024
• UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials - November 15th, 2024
• Avicanna Reports Q3 2024 - November 15th, 2024
• Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - November 15th, 2024
• MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in... - November 15th, 2024
• Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - November 15th, 2024
• Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) - November 15th, 2024
• Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - November 15th, 2024
• NINER Pharmaceutical Strengthens Global Presence with Strategic IV Fluid Supply Initiative for the U.S. and Latin American Markets - November 15th, 2024
• Bavarian Nordic Announces Interim Results for the First Nine Months of 2024 - November 15th, 2024
• ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer - October 21st, 2024
• Phase III trial results of novel triple combination pill for hypertension published in The Lancet - October 21st, 2024
• UPDATE -- Better Choice Company Chairman Issues Letter to Shareholders as Company Continues to Make Progress Towards the Closing of its SRx Health... - October 21st, 2024
• Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 - October 21st, 2024
• Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older - October 21st, 2024
• Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit - October 21st, 2024
• Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson - October 21st, 2024
• Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical... - October 21st, 2024
• DBV Technologies to Participate in Upcoming ACAAI 2024 Congress - October 21st, 2024
• Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study - October 21st, 2024
• Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended... - October 21st, 2024
• Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal - October 21st, 2024
• Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and... - October 21st, 2024
• NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS) - October 21st, 2024
• Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory... - October 21st, 2024
• Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and... - October 21st, 2024
• Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare - October 21st, 2024
• ViaNautis Appoints Ray Jupp as Chief Scientific Officer - October 21st, 2024
• AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer - October 21st, 2024
• Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update - October 21st, 2024
• Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The... - October 13th, 2024

Global News Feed Comments Off on Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio | November 15th, 2024

About... Dr. Matthew Watson

Categories

• Bone Marrow Stem Cells (2,954)
• Cardiac Stem Cells (1,269)
• Global News Feed (3,315)
• Integrative Medicine (105)
• IPS Cell Therapy (464)
• Nano medicine (2)
• Regenerative Medicine (44)
• Skin Stem Cells (2,198)
• Spinal Cord Stem Cells (950)
• Stem Cell Therapy (528)

Archives

Recommended Sites

• California Stem Cell Research
• Cord Blood Banking
• Gene Therapy Breakthroughs
• Immortality Medicine
• Medical School Review
• Nano Technology American Physicians
• Videos Of Stem Cell Therapy